US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Retinitis Pigmentosa · Dry Eye Disease · KPRX
KIORA PHARMACEUTICALS
KIORA PHARMACEUTICALS INC
KIORA PHARMACEUTICALS drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Encinitas, USA HQ
2013 Founded
18 Employees
Public company Type
KPRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Encinitas, USA
- Founded
- 2013
- Employees
- 18
- Programs
- 5
- Drugs
- 4
- Patents
- 4
KIORA PHARMACEUTICALS pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
KIORA PHARMACEUTICALS drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to KIORA PHARMACEUTICALS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Mechanism: Reducing agent.
- Mechanism
- Reducing agent